201 related articles for article (PubMed ID: 37961516)
1. Dissecting signaling regulators driving AXL-mediated bypass resistance and associated phenotypes by phosphosite perturbations.
Creixell M; Taylor SD; Gerritsen J; Bae SY; Jiang M; Augustin T; Loui M; Boixo C; Creixell P; White FM; Meyer AS
bioRxiv; 2023 Oct; ():. PubMed ID: 37961516
[TBL] [Abstract][Full Text] [Related]
2. An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
Byers LA; Diao L; Wang J; Saintigny P; Girard L; Peyton M; Shen L; Fan Y; Giri U; Tumula PK; Nilsson MB; Gudikote J; Tran H; Cardnell RJ; Bearss DJ; Warner SL; Foulks JM; Kanner SB; Gandhi V; Krett N; Rosen ST; Kim ES; Herbst RS; Blumenschein GR; Lee JJ; Lippman SM; Ang KK; Mills GB; Hong WK; Weinstein JN; Wistuba II; Coombes KR; Minna JD; Heymach JV
Clin Cancer Res; 2013 Jan; 19(1):279-90. PubMed ID: 23091115
[TBL] [Abstract][Full Text] [Related]
3.
Han SY; Zhao W; Han HB; Sun H; Xue D; Jiao YN; He XR; Jiang ST; Li PP
Oncotarget; 2017 Aug; 8(34):56893-56905. PubMed ID: 28915640
[TBL] [Abstract][Full Text] [Related]
4. Axl mediates acquired resistance of head and neck cancer cells to the epidermal growth factor receptor inhibitor erlotinib.
Giles KM; Kalinowski FC; Candy PA; Epis MR; Zhang PM; Redfern AD; Stuart LM; Goodall GJ; Leedman PJ
Mol Cancer Ther; 2013 Nov; 12(11):2541-58. PubMed ID: 24026012
[TBL] [Abstract][Full Text] [Related]
5. YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC.
Ghiso E; Migliore C; Ciciriello V; Morando E; Petrelli A; Corso S; De Luca E; Gatti G; Volante M; Giordano S
Neoplasia; 2017 Dec; 19(12):1012-1021. PubMed ID: 29136529
[TBL] [Abstract][Full Text] [Related]
6. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
7. AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation.
Yang YM; Jang Y; Lee SH; Kang B; Lim SM
Lung Cancer; 2020 Aug; 146():70-77. PubMed ID: 32521387
[TBL] [Abstract][Full Text] [Related]
8. The role of Axl in drug resistance and epithelial-to-mesenchymal transition of non-small cell lung carcinoma.
Wu F; Li J; Jang C; Wang J; Xiong J
Int J Clin Exp Pathol; 2014; 7(10):6653-61. PubMed ID: 25400744
[TBL] [Abstract][Full Text] [Related]
9. TGFβ promotes YAP-dependent AXL induction in mesenchymal-type lung cancer cells.
Choi JY; Lee H; Kwon EJ; Kong HJ; Kwon OS; Cha HJ
Mol Oncol; 2021 Feb; 15(2):679-696. PubMed ID: 33207077
[TBL] [Abstract][Full Text] [Related]
10. GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance.
Baumann C; Ullrich A; Torka R
Mol Oncol; 2017 Oct; 11(10):1430-1447. PubMed ID: 28675785
[TBL] [Abstract][Full Text] [Related]
11. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
12. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL.
Lay JD; Hong CC; Huang JS; Yang YY; Pao CY; Liu CH; Lai YP; Lai GM; Cheng AL; Su IJ; Chuang SE
Cancer Res; 2007 Apr; 67(8):3878-87. PubMed ID: 17440102
[TBL] [Abstract][Full Text] [Related]
13. AXL/CDCP1/SRC axis confers acquired resistance to osimertinib in lung cancer.
Murakami Y; Kusakabe D; Watari K; Kawahara A; Azuma K; Akiba J; Taniguchi M; Kuwano M; Ono M
Sci Rep; 2022 May; 12(1):8983. PubMed ID: 35643725
[TBL] [Abstract][Full Text] [Related]
14. The miR‑625‑3p/AXL axis induces non‑T790M acquired resistance to EGFR‑TKI via activation of the TGF‑β/Smad pathway and EMT in EGFR‑mutant non‑small cell lung cancer.
Du W; Sun L; Liu T; Zhu J; Zeng Y; Zhang Y; Wang X; Liu Z; Huang JA
Oncol Rep; 2020 Jul; 44(1):185-195. PubMed ID: 32319651
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance to EGFR tyrosine kinase inhibitors is mediated by the reactivation of STC2/JUN/AXL signaling in lung cancer.
Liu YN; Tsai MF; Wu SG; Chang TH; Tsai TH; Gow CH; Chang YL; Shih JY
Int J Cancer; 2019 Sep; 145(6):1609-1624. PubMed ID: 31162839
[TBL] [Abstract][Full Text] [Related]
16. Blockade of AXL activation overcomes acquired resistance to EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Wang F; Liu X; Bartholdy BA; Cheng H; Halmos B
Transl Cancer Res; 2019 Oct; 8(6):2425-2438. PubMed ID: 35116995
[TBL] [Abstract][Full Text] [Related]
17. Mechanism research of miR-34a regulates Axl in non-small-cell lung cancer with gefitinib-acquired resistance.
Xiong R; Sun XX; Wu HR; Xu GW; Wang GX; Sun XH; Xu MQ; Xie MR
Thorac Cancer; 2020 Jan; 11(1):156-165. PubMed ID: 31777195
[TBL] [Abstract][Full Text] [Related]
18. ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT.
Debruyne DN; Bhatnagar N; Sharma B; Luther W; Moore NF; Cheung NK; Gray NS; George RE
Oncogene; 2016 Jul; 35(28):3681-91. PubMed ID: 26616860
[TBL] [Abstract][Full Text] [Related]
19. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
Zhang Z; Lee JC; Lin L; Olivas V; Au V; LaFramboise T; Abdel-Rahman M; Wang X; Levine AD; Rho JK; Choi YJ; Choi CM; Kim SW; Jang SJ; Park YS; Kim WS; Lee DH; Lee JS; Miller VA; Arcila M; Ladanyi M; Moonsamy P; Sawyers C; Boggon TJ; Ma PC; Costa C; Taron M; Rosell R; Halmos B; Bivona TG
Nat Genet; 2012 Jul; 44(8):852-60. PubMed ID: 22751098
[TBL] [Abstract][Full Text] [Related]
20. Integrin β3 Promotes Resistance to EGFR-TKI in Non-Small-Cell Lung Cancer by Upregulating AXL through the YAP Pathway.
Sun Q; Lu Z; Zhang Y; Xue D; Xia H; She J; Li F
Cells; 2022 Jun; 11(13):. PubMed ID: 35805163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
